|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Ocular Physiology | |||||
| Intraocular Pressure | |||||
| Regional Blood Flow | |||||
| 2 | Interventions listed in this trial | ||||
| Latanoprost 0.005%, Xalatan® | |||||
| Placebo | |||||
| 3 | Additional drug interventions recognized in this trial | ||||
| Latanoprost | |||||
| 4 | More general drug interventions related to this trial | ||||
| Antihypertensive Agents | |||||
| Cardiovascular Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| Medical University of Vienna | |||||